Following Chinese patients newly diagnosed with multiple myeloma and their immunotherapy treatment
Follows about 500 adults in China newly diagnosed with multiple myeloma who receive immunotherapy.
Plain-language title generated from the registry record
Registry title: Real-world Immuno-therapy in Chinese Newly Diagnosed Multiple Myeloma Patients
Key facts
- Where
- Beijing, ChinaSee the site
Where in China
- Peking University People's HospitalBeijing, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Peking University People's Hospital
- Trial code
- NCT07296627
- Record updated
- 22 December 2025
- Original description
To conduct a multicenter, prospective observational cohort study to investigate first-line immunotherapy patterns and clinical outcomes in NDMM patients in China. Leveraging the extensive patient resources of China's large center for blood disorders, the investigator will recruit approximately 500 NDMM patients to establish an NDMM patient cohort. The investigator will collect data on disease characteristics, treatment patterns, and clinical outcomes through one year of clinical follow-up. Further long-term follow-up is needed to obtain survival status and causes of death, so as to provide essential evidence for optimizing and improving patients' prognosis in clinical individualized treatment.Read full original descriptionShow less
A Prospective Study for Chinese Newly Diagnosed Multiple Myeloma Patients Treated With Immuno-therapy in Real-world Setting
To conduct a multicenter, prospective observational cohort study to investigate first-line immunotherapy patterns and clinical outcomes in NDMM patients in China. Leveraging the extensive patient resources of China's large center for blood disorders, the investigator will recruit approximately 500 NDMM patients to establish an NDMM patient cohort. The investigator will collect data on disease characteristics, treatment patterns, and clinical outcomes through one year of clinical follow-up. Further long-term follow-up is needed to obtain survival status and causes of death, so as to provide essential evidence for optimizing and improving patients' prognosis in clinical individualized treatment.
Inclusion: Newly diagnosed multiple myeloma (NDMM); Plan to receive first-line immunotherapy at the respective research center; First-line immunotherapy includes proteasome inhibitors (PI), immunomodulatory drugs (IMiDs), or anti-CD38 monoclonal antibodies, used alone or in combination with each other or with other treatments; Age ≥ 18 years; Ability to understand the purpose of the study and follow-up process; Willingness to provide signed and dated written informed consent.
Exclusion: Patients who did not receive any follow-up after initial diagnosis.